THE USE OF GLP-1 ANALOGUES IN BLOOD GLUCOSE CONTROL AND THEIR CARDIOVASCULAR BENEFITS: A REVIEW OF THE LITERATURE

Abstract

Introduction: Obesity is configured as a chronic disease that generates systemic impacts and the use of GLP-1 analogs is considered as an adjuvant therapy, primarily for glycemic control, and goes beyond, providing cardiovascular benefits and its mechanisms, among other relevant guidelines. Objectives: To analyze the effects of GLP-1 analogs beyond the hypoglycemic effect, associating them with cardiovascular disease prevention, blood lipid-lowering, and anti-inflammatory action. Methodology: Narrative review, with a search of articles, research, and periodicals, in MEDLINE, SciELO, and LILACS databases. The descriptors "obesity", "glycemic control", "GLP-1 analogs" and "cardiovascular" were used together with the Boolean operator AND. Inclusion criteria were publications dated within the last seven years, in Portuguese or English, and with full text. The exclusion criteria were based on duplicate or repetitive texts, as well as those that explored the theme without considering the central core (GLP-1 analogs and glycemic control). Results: It is noted that GLP-1 analogs are theoretically safe for glycemic control, constituting possible alternatives to the aforementioned substances.